DEZ-001: Phase IIb data

Additional data from the double-blind, dose-ranging, European Phase IIb TULIP trial in 364 patients with mild dyslipidemia showed that once-daily 1, 2.5, 5 and 10 mg oral TA-8895 alone reduced LDL-C b...